Avalyn Pharma Inc. officer Douglas Carlson filed a Form 144 notice on November 17, 2026, disclosing a proposed sale of 14,875 shares of common stock acquired through the exercise of stock options on the same date.
Key Highlights
- Filer and role: Douglas Carlson, identified as an officer of Avalyn Pharma Inc.
- Shares proposed for sale: 14,875 shares of common stock, with an aggregate market value of $442,680.00.
- Acquisition method: Shares were acquired on November 17, 2026, through the exercise of stock options granted by the issuer, with payment made in cash.
- Approximate date of sale: November 17, 2026, through broker Morgan Stanley Smith Barney LLC Executive Financial Services.
- 10b5-1 plan: The notice indicates a Rule 10b5-1 plan adoption date of July 30, 2026.
- Shares outstanding: 44,521,494 shares of common stock outstanding at the time of filing, according to the notice.
- Prior sales: No securities of the issuer were sold by Carlson in the three months preceding this notice.
Avalyn Pharma Officer Files Rule 144 Notice for Option-Exercised Shares
According to the Form 144 notice filed with the U.S. Securities and Exchange Commission, Douglas Carlson, an officer of Avalyn Pharma Inc. (NASDAQ:AVLN), proposed to sell 14,875 shares of the company's common stock. The filing lists an aggregate market value of $442,680.00 for the shares to be sold. The proposed sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, on or about November 17, 2026.
The filing discloses that the 14,875 shares were acquired on November 17, 2026, via the exercise of stock options issued by the issuer, with the full purchase price paid in cash on the same date. Avalyn Pharma is listed as the person from whom the securities were acquired. The notice states that Carlson had no reportable sales of Avalyn Pharma securities during the three months prior to this filing.
The filing also indicates that Carlson is relying on a Rule 10b5-1 trading plan, with an adoption date of July 30, 2026. By signing the notice, Carlson represented, as of that plan adoption date, that he did not possess material adverse information about Avalyn Pharma's current and prospective operations that had not been publicly disclosed. Avalyn Pharma's issuer address is listed as 105 W First Street, Boston, Massachusetts 02127.
What Was Disclosed
Avalyn Pharma officer Douglas Carlson filed a Form 144 notice proposing to sell 14,875 shares of common stock, valued at $442,680.00 in aggregate, acquired through stock option exercise on November 17, 2026, under a Rule 10b5-1 plan adopted July 30, 2026.




Please wait processing your request...